[Form 4] Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock Insider Trading Activity
Kua Khai Loon, identified on the form as a Director, reported a sale of 19,054 shares of Cyclacel Pharmaceuticals common stock on 09/05/2025 at a price of $7.01 per share. After the reported transaction the filing shows 385,411 shares beneficially owned, held directly. The Form 4 is signed and dated 09/10/2025. The filing discloses the transaction type as a sale and provides the transaction price and post-transaction holdings; no derivative transactions or additional explanatory details are included.
Kua Khai Loon, indicato nel modulo come Director, ha dichiarato la vendita di 19.054 azioni ordinarie di Cyclacel Pharmaceuticals il 09/05/2025 al prezzo di $7,01 per azione. Dopo l'operazione riportata il documento indica la detenzione beneficiaria di 385.411 azioni, possedute direttamente. Il Modulo 4 è firmato e datato 09/10/2025. La comunicazione descrive la transazione come una vendita e fornisce il prezzo e le partecipazioni successive all'operazione; non sono incluse transazioni su derivati né dettagli esplicativi aggiuntivi.
Kua Khai Loon, identificado en el formulario como Director, informó la venta de 19.054 acciones ordinarias de Cyclacel Pharmaceuticals el 09/05/2025 a un precio de $7,01 por acción. Tras la operación informada, la presentación muestra la titularidad beneficiaria de 385.411 acciones, poseídas directamente. El Formulario 4 está firmado y fechado el 09/10/2025. La presentación declara que se trata de una venta y proporciona el precio de la transacción y las tenencias posteriores; no se incluyen operaciones con derivados ni detalles explicativos adicionales.
Kua Khai Loon은(는) 양식에서 Director로 기재되어 있으며, 2025년 9월 5일에 Cyclacel Pharmaceuticals 보통주 19,054주를 주당 $7.01에 매도했다고 보고했습니다. 보고된 거래 이후 해당 제출서류에는 385,411주를 직접 실질적으로 보유하고 있는 것으로 표시되어 있습니다. Form 4는 2025년 9월 10일에 서명 및 날짜가 기재되어 제출되었습니다. 제출서류는 거래 유형을 매도로 기재하고 거래 가격과 거래 후 보유 수량을 제공하며, 파생상품 거래나 추가 설명은 포함되지 않았습니다.
Kua Khai Loon, identifié sur le formulaire comme Director, a déclaré la vente de 19 054 actions ordinaires de Cyclacel Pharmaceuticals le 09/05/2025 au prix de 7,01 $ par action. Après la transaction signalée, le dépôt indique la propriété bénéficiaire de 385 411 actions, détenues directement. Le Formulaire 4 est signé et daté du 10/09/2025. Le dépôt qualifie la transaction de vente et fournit le prix et les avoirs post-transaction ; aucune opération sur dérivés ni détail explicatif supplémentaire n'est fourni.
Kua Khai Loon, im Formular als Director geführt, meldete den Verkauf von 19.054 Aktien der Stammaktien von Cyclacel Pharmaceuticals am 09.05.2025 zu einem Preis von $7,01 pro Aktie. Nach der gemeldeten Transaktion weist die Einreichung einen wirtschaftlichen Besitz von 385.411 Aktien aus, die direkt gehalten werden. Das Formular 4 ist unterschrieben und datiert auf den 10.09.2025. Die Meldung gibt die Transaktion als Verkauf an und nennt Preis sowie die Bestände nach der Transaktion; derivative Geschäfte oder zusätzliche erläuternde Angaben sind nicht enthalten.
- Timely disclosure of an insider sale including transaction date, price, and post-transaction holdings
- Reporting person identified (Kua Khai Loon) and relationship to issuer (Director) are stated
- No explanation provided for the sale and no indication of a Rule 10b5-1 plan
- Materiality cannot be assessed from this Form 4 alone because outstanding share count or context is not provided
Insights
TL;DR: A director sold 19,054 shares at $7.01, leaving 385,411 shares; this routine disclosure is factual and provides transparency.
The Form 4 reports a straightforward insider sale with explicit quantities and price: 19,054 shares sold at $7.01 on 09/05/2025, reducing direct holdings to 385,411 shares. From a trading disclosure perspective, the filing meets Section 16 requirements by reporting the date, price, and post-transaction holdings. The document does not include any 10b5-1 plan checkbox or additional narrative explaining the rationale, and no derivative instruments are reported. Without context on total outstanding shares or recent trading patterns, the sale's relative materiality to valuation cannot be assessed from this filing alone.
TL;DR: Insider complied with reporting requirements; sale by a director is disclosed but the filing supplies no explanation of intent.
The filing indicates compliance with required disclosure mechanics: reporter identity, relationship to issuer, transaction date, price, and resulting beneficial ownership are all stated. The reporting person is identified as a director. The absence of any checked box indicating a Rule 10b5-1 trading plan or other explanatory statement means the document contains no affirmative defense or stated pre-arrangement. For governance monitoring, this provides necessary transparency but does not explain whether the sale was routine, personal, or strategic.
Kua Khai Loon, indicato nel modulo come Director, ha dichiarato la vendita di 19.054 azioni ordinarie di Cyclacel Pharmaceuticals il 09/05/2025 al prezzo di $7,01 per azione. Dopo l'operazione riportata il documento indica la detenzione beneficiaria di 385.411 azioni, possedute direttamente. Il Modulo 4 è firmato e datato 09/10/2025. La comunicazione descrive la transazione come una vendita e fornisce il prezzo e le partecipazioni successive all'operazione; non sono incluse transazioni su derivati né dettagli esplicativi aggiuntivi.
Kua Khai Loon, identificado en el formulario como Director, informó la venta de 19.054 acciones ordinarias de Cyclacel Pharmaceuticals el 09/05/2025 a un precio de $7,01 por acción. Tras la operación informada, la presentación muestra la titularidad beneficiaria de 385.411 acciones, poseídas directamente. El Formulario 4 está firmado y fechado el 09/10/2025. La presentación declara que se trata de una venta y proporciona el precio de la transacción y las tenencias posteriores; no se incluyen operaciones con derivados ni detalles explicativos adicionales.
Kua Khai Loon은(는) 양식에서 Director로 기재되어 있으며, 2025년 9월 5일에 Cyclacel Pharmaceuticals 보통주 19,054주를 주당 $7.01에 매도했다고 보고했습니다. 보고된 거래 이후 해당 제출서류에는 385,411주를 직접 실질적으로 보유하고 있는 것으로 표시되어 있습니다. Form 4는 2025년 9월 10일에 서명 및 날짜가 기재되어 제출되었습니다. 제출서류는 거래 유형을 매도로 기재하고 거래 가격과 거래 후 보유 수량을 제공하며, 파생상품 거래나 추가 설명은 포함되지 않았습니다.
Kua Khai Loon, identifié sur le formulaire comme Director, a déclaré la vente de 19 054 actions ordinaires de Cyclacel Pharmaceuticals le 09/05/2025 au prix de 7,01 $ par action. Après la transaction signalée, le dépôt indique la propriété bénéficiaire de 385 411 actions, détenues directement. Le Formulaire 4 est signé et daté du 10/09/2025. Le dépôt qualifie la transaction de vente et fournit le prix et les avoirs post-transaction ; aucune opération sur dérivés ni détail explicatif supplémentaire n'est fourni.
Kua Khai Loon, im Formular als Director geführt, meldete den Verkauf von 19.054 Aktien der Stammaktien von Cyclacel Pharmaceuticals am 09.05.2025 zu einem Preis von $7,01 pro Aktie. Nach der gemeldeten Transaktion weist die Einreichung einen wirtschaftlichen Besitz von 385.411 Aktien aus, die direkt gehalten werden. Das Formular 4 ist unterschrieben und datiert auf den 10.09.2025. Die Meldung gibt die Transaktion als Verkauf an und nennt Preis sowie die Bestände nach der Transaktion; derivative Geschäfte oder zusätzliche erläuternde Angaben sind nicht enthalten.
FAQ
What did Kua Khai Loon report on the Form 4 for Cyclacel Pharmaceuticals (CYCCP)?
What is the reporting person's relationship to the issuer on this Form 4?
Did the Form 4 disclose any derivative securities or option transactions?
Is there an indication this sale was made under a 10b5-1 trading plan?
When was the Form 4 signed?
